封面
市场调查报告书
商品编码
1738289

标靶癌症治疗市场-全球产业规模、份额、趋势、机会及预测,依治疗类型、疾病适应症、最终用户、地区及竞争情况细分,2020-2030 年预测

Targeted Cancer Therapy Market - Global Industry Size, Share, Trends, Opportunity & Forecast, Segmented By Therapy Type, By Disease Indication, By End User, By Region & Competition, 2020-2030F

出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

2024 年全球标靶癌症治疗市场规模为 165.5 亿美元,预计到 2030 年将达到 252.4 亿美元,复合年增长率为 7.25%。该市场是更广泛的肿瘤学领域的重要组成部分,强调针对导致癌症进展的特定基因突变、蛋白质或细胞环境的精准治疗方法。标靶治疗旨在最大限度地提高治疗效果,同时最大限度地减少传统化疗和放疗常见的附带损害。本产业涵盖单株抗体、激酶抑制剂、免疫检查点抑制剂和小分子等一系列疗法。持续的创新、研发投入和积极的临床试验管线正在加速产品开发,从而促进改善患者预后并扩大各种癌症类型的治疗可能性。

市场概览
预测期 2026-2030
2024年市场规模 165.5亿美元
2030年市场规模 252.4亿美元
2025-2030 年复合年增长率 7.25%
成长最快的领域 乳癌
最大的市场 北美洲

关键市场驱动因素

各类癌症发生率不断上升

主要市场挑战

标靶治疗的高成本和副作用

主要市场趋势

基因组分析与精准医疗的进展

目录

第 1 章:产品概述

第二章:研究方法

第三章:执行摘要

第四章:顾客之声

第五章:癌症标靶治疗市场展望

  • 市场规模和预测
    • 按价值
  • 市场占有率和预测
    • 依治疗类型(荷尔蒙疗法、单株抗体、讯号传导抑制剂、基因表现调节剂、凋亡抑制剂等)
    • 依疾病适应症(肺癌、乳癌、大肠癌、白血病、黑色素瘤、淋巴瘤、其他)
    • 按最终使用者(医院和诊所、癌症和放射治疗中心、学术和研究机构)
    • 按地区
    • 按公司分类(2024)
  • 市场地图

第六章:北美标靶癌症治疗市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 北美:国家分析
    • 美国
    • 加拿大
    • 墨西哥

第七章:欧洲标靶癌症治疗市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 欧洲:国家分析
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙

第八章:亚太地区癌症标靶治疗市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 亚太地区:国家分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲

第九章:南美洲标靶癌症治疗市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 南美洲:国家分析
    • 巴西
    • 阿根廷
    • 哥伦比亚

第 10 章:中东和非洲标靶癌症治疗市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • MEA:国家分析
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋

第 11 章:市场动态

  • 驱动程式
  • 挑战

第 12 章:市场趋势与发展

  • 最新动态
  • 产品发布
  • 併购

第 13 章:全球标靶癌症治疗市场:SWOT 分析

第 14 章:竞争格局

  • Amgen Inc.
  • AstraZeneca plc
  • Bayer AG
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline plc
  • Johnson & Johnson Service Inc.
  • Merck & Co. Inc.
  • Novartis AG
  • Pfizer Inc.

第 15 章:策略建议

第16章调查会社について・免责事项

简介目录
Product Code: 8113

The Global Targeted Cancer Therapy Market was valued at USD 16.55 Billion in 2024 and is projected to reach USD 25.24 Billion by 2030, growing at a CAGR of 7.25%. This market forms a crucial segment of the broader oncology landscape, emphasizing precision treatment approaches that act on specific genetic mutations, proteins, or cellular environments contributing to cancer progression. Targeted therapies aim to maximize treatment efficacy while minimizing collateral damage often seen with traditional chemotherapy and radiation. The industry includes an array of modalities such as monoclonal antibodies, kinase inhibitors, immune checkpoint inhibitors, and small molecules. Continued innovation, R&D investment, and active clinical trial pipelines are accelerating product development, thereby fostering improved patient outcomes and expanding therapeutic possibilities across various cancer types.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 16.55 Billion
Market Size 2030USD 25.24 Billion
CAGR 2025-20307.25%
Fastest Growing SegmentBreast Cancer
Largest MarketNorth America

Key Market Drivers

Increasing Prevalence of Various Type of Cancers

Rising cancer prevalence globally is a major force fueling the demand for targeted cancer therapies. As of 2020, cancer accounted for nearly 10 million deaths annually, making it a dominant health and economic concern. Pediatric cancer remains a high-priority area, with roughly 400,000 new diagnoses each year. Patterns of incidence vary by geography, with cervical cancer topping the list in 23 countries, reflecting inequalities in HPV vaccination and screening. This variation signals untapped markets for tailored diagnostics and therapies. Lung cancer, representing about 12.4% of all new cancer cases, remains the deadliest, contributing to 18.7% of all cancer-related fatalities. As aging populations, lifestyle shifts, and environmental exposures drive global cancer rates upward, targeted therapies provide more effective, less toxic alternatives to conventional treatments. Their ability to deliver personalized, gene-specific interventions positions them as essential tools in modern oncology, especially in light of these growing epidemiological trends.

Key Market Challenges

High Cost and Side Effects Associated with the Targeted Therapies

The considerable cost of targeted cancer treatments presents a substantial hurdle to widespread adoption. Advanced therapies such as monoclonal antibodies and gene modulators demand high manufacturing investment and specialized administration, resulting in elevated prices for patients and healthcare systems. According to the American Association for Cancer Research, the U.S. could see national cancer-related costs exceed USD 245 billion by 2030-an increase of over 30% since 2015. Patients undergoing initial, ongoing, or end-of-life cancer care can incur average annual costs ranging from USD 5,300 to over USD 41,800. This economic burden affects access to care and can lead to financial distress for both patients and healthcare providers. Additionally, while targeted therapies are generally safer than traditional chemotherapy, they are not devoid of side effects, including immune-related adverse events or organ toxicity. These challenges call for innovative cost-control strategies, reimbursement policy revisions, and research into affordable alternatives to sustain market growth.

Key Market Trends

Advancements In Genomic Profiling and Precision Medicine

The integration of genomic profiling and precision medicine is transforming cancer treatment, driving greater adoption of targeted therapies. Next-generation sequencing (NGS) and liquid biopsy technologies now enable precise identification of genetic mutations that drive cancer, allowing clinicians to tailor treatment plans based on each patient's unique tumor profile. These innovations have led to more effective, personalized therapies with fewer adverse effects. Precision medicine is also becoming instrumental in tracking disease progression and resistance patterns, enabling real-time adjustments to treatment. As these tools become more accessible, healthcare systems worldwide are increasingly implementing genomic-based protocols. This evolution in oncology practice underscores the growing reliance on targeted treatments and supports their rising use as a mainstay in cancer care strategies.

Key Market Players

  • Amgen Inc.
  • AstraZeneca plc
  • Bayer AG
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline plc
  • Johnson & Johnson Service Inc.
  • Merck & Co. Inc.
  • Novartis AG
  • Pfizer Inc.

Report Scope:

In this report, the Global Targeted Cancer Therapy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Targeted Cancer Therapy Market, By Therapy Type:

  • Hormone Therapies
  • Monoclonal Antibodies
  • Signal Transduction Inhibitors
  • Gene Expression Modulators
  • Apoptosis Inhibitors
  • Others

Targeted Cancer Therapy Market, By Disease Indication:

  • Lung Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Leukemia
  • Melanoma
  • Lymphoma
  • Others

Targeted Cancer Therapy Market, By End User:

  • Hospitals & Clinics
  • Cancer & Radiation Therapy Centers
  • Academic & Research Institutions

Targeted Cancer Therapy Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Targeted Cancer Therapy Market.

Available Customizations:

Global Targeted Cancer Therapy market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Targeted Cancer Therapy Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Therapy Type (Hormone Therapies, Monoclonal Antibodies, Signal Transduction Inhibitors, Gene Expression Modulators, Apoptosis Inhibitors, Others)
    • 5.2.2. By Disease Indication (Lung Cancer, Breast Cancer, Colorectal Cancer, Leukemia, Melanoma, Lymphoma, Others)
    • 5.2.3. By End User (Hospitals & Clinics, Cancer & Radiation Therapy Centers, Academic & Research Institutions)
    • 5.2.4. By Region
    • 5.2.5. By Company (2024)
  • 5.3. Market Map

6. North America Targeted Cancer Therapy Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Therapy Type
    • 6.2.2. By Disease Indication
    • 6.2.3. By End User
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Targeted Cancer Therapy Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Therapy Type
        • 6.3.1.2.2. By Disease Indication
        • 6.3.1.2.3. By End User
    • 6.3.2. Canada Targeted Cancer Therapy Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Therapy Type
        • 6.3.2.2.2. By Disease Indication
        • 6.3.2.2.3. By End User
    • 6.3.3. Mexico Targeted Cancer Therapy Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Therapy Type
        • 6.3.3.2.2. By Disease Indication
        • 6.3.3.2.3. By End User

7. Europe Targeted Cancer Therapy Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Therapy Type
    • 7.2.2. By Disease Indication
    • 7.2.3. By End User
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Targeted Cancer Therapy Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Therapy Type
        • 7.3.1.2.2. By Disease Indication
        • 7.3.1.2.3. By End User
    • 7.3.2. United Kingdom Targeted Cancer Therapy Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Therapy Type
        • 7.3.2.2.2. By Disease Indication
        • 7.3.2.2.3. By End User
    • 7.3.3. Italy Targeted Cancer Therapy Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Therapy Type
        • 7.3.3.2.2. By Disease Indication
        • 7.3.3.2.3. By End User
    • 7.3.4. France Targeted Cancer Therapy Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Therapy Type
        • 7.3.4.2.2. By Disease Indication
        • 7.3.4.2.3. By End User
    • 7.3.5. Spain Targeted Cancer Therapy Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Therapy Type
        • 7.3.5.2.2. By Disease Indication
        • 7.3.5.2.3. By End User

8. Asia-Pacific Targeted Cancer Therapy Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Therapy Type
    • 8.2.2. By Disease Indication
    • 8.2.3. By End User
    • 8.2.4. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Targeted Cancer Therapy Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Therapy Type
        • 8.3.1.2.2. By Disease Indication
        • 8.3.1.2.3. By End User
    • 8.3.2. India Targeted Cancer Therapy Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Therapy Type
        • 8.3.2.2.2. By Disease Indication
        • 8.3.2.2.3. By End User
    • 8.3.3. Japan Targeted Cancer Therapy Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Therapy Type
        • 8.3.3.2.2. By Disease Indication
        • 8.3.3.2.3. By End User
    • 8.3.4. South Korea Targeted Cancer Therapy Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Therapy Type
        • 8.3.4.2.2. By Disease Indication
        • 8.3.4.2.3. By End User
    • 8.3.5. Australia Targeted Cancer Therapy Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Therapy Type
        • 8.3.5.2.2. By Disease Indication
        • 8.3.5.2.3. By End User

9. South America Targeted Cancer Therapy Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Therapy Type
    • 9.2.2. By Disease Indication
    • 9.2.3. By End User
    • 9.2.4. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Targeted Cancer Therapy Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Therapy Type
        • 9.3.1.2.2. By Disease Indication
        • 9.3.1.2.3. By End User
    • 9.3.2. Argentina Targeted Cancer Therapy Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Therapy Type
        • 9.3.2.2.2. By Disease Indication
        • 9.3.2.2.3. By End User
    • 9.3.3. Colombia Targeted Cancer Therapy Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Therapy Type
        • 9.3.3.2.2. By Disease Indication
        • 9.3.3.2.3. By End User

10. Middle East and Africa Targeted Cancer Therapy Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Therapy Type
    • 10.2.2. By Disease Indication
    • 10.2.3. By End User
    • 10.2.4. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Targeted Cancer Therapy Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Therapy Type
        • 10.3.1.2.2. By Disease Indication
        • 10.3.1.2.3. By End User
    • 10.3.2. Saudi Arabia Targeted Cancer Therapy Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Therapy Type
        • 10.3.2.2.2. By Disease Indication
        • 10.3.2.2.3. By End User
    • 10.3.3. UAE Targeted Cancer Therapy Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Therapy Type
        • 10.3.3.2.2. By Disease Indication
        • 10.3.3.2.3. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Developments
  • 12.2. Product Launches
  • 12.3. Mergers & Acquisitions

13. Global Targeted Cancer Therapy Market: SWOT Analysis

14. Competitive Landscape

  • 14.1. Amgen Inc.
    • 14.1.1. Business Overview
    • 14.1.2. Product & Service Offerings
    • 14.1.3. Recent Developments
    • 14.1.4. Financials (If Listed)
    • 14.1.5. Key Personnel
    • 14.1.6. SWOT Analysis
  • 14.2. AstraZeneca plc
  • 14.3. Bayer AG
  • 14.4. Bristol-Myers Squibb Company
  • 14.5. F. Hoffmann-La Roche Ltd
  • 14.6. GlaxoSmithKline plc
  • 14.7. Johnson & Johnson Service Inc.
  • 14.8. Merck & Co. Inc.
  • 14.9. Novartis AG
  • 14.10.Pfizer Inc.

15. Strategic Recommendations

16. About Us & Disclaimer